top of page

Longevity and AI Scientist Proposes a Strategy and Clinical Trials for Geroprotectors and Deep Immunological Aging Clocks to Combat COVID-19

MARCH 31, 2020

Longevity and AI Scientist Proposes a Strategy and Clinical Trials for Geroprotectors and Deep Immunological Aging Clocks to Combat COVID-19

31st of March, Tuesday (2:0PM GMT), London, UK - The Biogerontology Research Foundation, a registered UK charity supporting and promoting aging and longevity research worldwide since 2008, today announced the publication of a paper titled “Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections” in the leading journal Aging.

Vaccines and therapeutic solutions for COVID-19 are still far from the clinic and will not provide complete protection, and likely to be less effective in the elderly. Recent BBC article notes “It will, almost inevitably, be less successful in older people. This is not because of the vaccine itself, but aged immune systems do not respond as well to immunisation. We see this every year with the flu jab.

The author of the study, Alex Zhavoronkov, PhD, the chief scientist of the Biogerontology Research Foundation and the CEO of an artificial intelligence company Insilico Medicine proposed calling SARS-CoV-2 and other infections that are more infectious and harmful to the elderly as gerophilic and gerolavic infections.

He also proposed a strategy for repurposing known geroprotectors such as rapamycin, nicotinamide riboside, nicotinamide mononucleotide, metformin, and other drugs with the known safety profile for prevention of SARS-CoV-2 infection. The scientist analyzed the prior clinical studies of everolimus (RAD001) in healthy elderly, and previous evidence showing paradoxical immunopotentiation effects of rapamycin and proposed additional clinical trials for these molecules in the healthy elderly population.

Zhavoronkov also proposed the use of inexpensive and minimally-invasive deep aging clocks to track the efficacy of these preventative geroprotective interventions and to stratify the patients by predicted severity of COVID-19.

“We are pursuing several strategies for drug discovery and repurposing using the latest advances in artificial intelligence integrated into our battle-tested discovery platform. However, it is clear that COVID-19 is a gerophilic and gerolavic disease. It is more severe and lethal in the elderly. Aging research yields insights that may not only help with COVID-19 but may help prevent many other diseases and increase productive longevity and re-ignite the economy”, said Alex Zhavoronkov, PhD.

Previous studies by the BGRF scientists including “Biomedical Progress Rates as New Parameters for Models of Economic Growth in Developed Countries”, and books including “The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy” show that extending productive longevity in the developed countries will lead to unprecedented economic growth.

“Most of the companies and institutions are racing to create vaccines or drugs that target COVID directly. But these interventions will not offer complete protection. We see that children and very young people do not have severe symptoms. Geroprotectors may help improve the odds for the elderly. And once the epidemic subsides, we will need to find new ways to boost the economy and there are established models showing that the best way to grow the economy is by increasing healthy productive longevity”, said Dmitry Kaminskiy, managing trustee of the Biogerontology Research Foundation.

“This is the first review highlighting geroprotective strategies that may decrease the disease burden of gerolavic infections such as COVID-19. It presents a case for further research and clinical studies to validate markers of biological age in the context of viral infections. Ageing Research at King’s College (ARK) is partnering with Biogerontology Research Foundation and Insilico Medicine to identify mechanisms by which geroprotectors enhance resilience against infections and reduce the severity of symptoms. The proposed research will acutely help physicians treat COVID-19, protect the elderly and benefit long term global health and longevity”, said Dr.Richard Siow, Director of ARK and former Vice-Dean, Faculty of Life Sciences & Medicine, King’s College London.

About the Biogerontology Research Foundation

The Biogerontology Research Foundation is the UK's leading non-profit focused on Longevity, supporting ageing research and multiple initiatives relating to advancing Healthy Longevity and expediting the coming paradigm shift from disease treatment to personalized precision prevention. It was the main initial donor that provided financial and organisational support to Longevity International UK for the purpose of establishing the UK All-Party Parliamentary Group for Longevity, and to Ageing Research at King's College (ARK) for the purpose of establishing the Longevity AI Consortium. It was also actively involved in the successful initiative of adding a new extension code for "ageing-related diseases" accepted in 2018 by the World Health Organization during the last revisions of its International Classification of Diseases framework.

About Alex Zhavoronkov, PhD

Alex Zhavoronkov, PhD, is the chief scientist of the Biogerontology Research Foundation and is the founder and CEO of Insilico Medicine (, a leader in next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. Since 2015 he has invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he has published over 130 peer-reviewed research papers, and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and co-chairs the Annual Aging Research, Drug Discovery and AI Forum at Basel Life, one of Europe's largest industry events in drug discovery (7th annual to be hosted in Columbia University, September 2-4, 2020,

Press enquiries

All enquiries should be

directed to

bottom of page